- The Myeloma Beacon - https://myelomabeacon.org -
Kyprolis (carfilzomib, PR-171)
By: Jessica Langholtz; Published: June 4, 2009 @ 7:01 pm | Comments Disabled
| Brand Name: | Kyprolis |
| Generic Name: | carfilzomib |
| Useful Links: | News articles [1], forum discussions [2] |
| Code Name: | PR-171 |
| Company: | Onyx Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Kyprolis, which is a second-generation proteasome inhibitor, selectively targets the enzymes that break down important proteins in cancerous cells. Multiple early-stage studies have shown that carfilzomib has an encouraging safety profile, with low levels of neuropathy (a common side effect for many myeloma treatments). A Phase 2 trial with relapsed and refractory myeloma patients has recently closed enrollment, and results are expected in late 2010.
Clinical Trials:
For a list of clinical trials studying carfilzomib for the treatment of multiple myeloma, see ClinicalTrials.gov [3].
Official Web site for Carfilzomib: http://www.kyprolis.com [4]
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2009/06/04/carfilzomib/
URLs in this post:
[1] News articles: https://myelomabeacon.org/tag/kyprolis/
[2] forum discussions: http://bit.ly/QbdjKP
[3] ClinicalTrials.gov: http://clinicaltrials.gov/ct2/results?term=carfilzomib+myeloma
[4] http://www.kyprolis.com: http://www.kyprolis.com
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.